Beam Therapeutics Inc
NASDAQ:BEAM

Watchlist Manager
Beam Therapeutics Inc Logo
Beam Therapeutics Inc
NASDAQ:BEAM
Watchlist
Price: 28.7 USD -1.07% Market Closed
Market Cap: 2.4B USD
Have any thoughts about
Beam Therapeutics Inc?
Write Note

Beam Therapeutics Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Beam Therapeutics Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Beam Therapeutics Inc
NASDAQ:BEAM
Accrued Liabilities
$124m
CAGR 3-Years
76%
CAGR 5-Years
136%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Accrued Liabilities
$14.6B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accrued Liabilities
$3.2B
CAGR 3-Years
27%
CAGR 5-Years
22%
CAGR 10-Years
28%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accrued Liabilities
$2.5B
CAGR 3-Years
7%
CAGR 5-Years
25%
CAGR 10-Years
24%
No Stocks Found

Beam Therapeutics Inc
Glance View

Market Cap
2.4B USD
Industry
Biotechnology

Beam Therapeutics Inc. stands at the cutting edge of the biotechnology sector, pioneering the fascinating realm of gene editing through its unique approach known as base editing. Conceived from the intellectual explorations of world-renowned scientists, Beam Therapeutics intertwines science and innovation to redesign the genetic fabric that defines life. Unlike traditional gene-editing techniques that involve breaking the DNA strands, Beam’s base editing is precise and subtle, modifying individual letters of the genetic code without introducing double-stranded breaks. This precision technology has significant implications, offering potential treatments for a spectrum of genetic disorders that have long eluded medical science. The company’s business model is intricately linked to the commercialization of its novel base editing platforms and the development of therapeutic candidates targeting critical genetic diseases. By strategically partnering with pharmaceutical giants, Beam Therapeutics leverages its cutting-edge technology to stimulate revenue streams through collaborations and licensing agreements. Additionally, the company aims to navigate the complex pathways of regulatory approval, advancing its drug candidates from laboratory research through clinical trials towards eventual market rollouts. As such, Beam Therapeutics is not merely focused on scientific discovery but is equally committed to transforming these breakthroughs into viable products that can, one day, redefine the clinical landscape of genetic medicine.

BEAM Intrinsic Value
9.68 USD
Overvaluation 66%
Intrinsic Value
Price

See Also

What is Beam Therapeutics Inc's Accrued Liabilities?
Accrued Liabilities
124m USD

Based on the financial report for Dec 31, 2023, Beam Therapeutics Inc's Accrued Liabilities amounts to 124m USD.

What is Beam Therapeutics Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
136%

Over the last year, the Accrued Liabilities growth was 112%. The average annual Accrued Liabilities growth rates for Beam Therapeutics Inc have been 76% over the past three years , 136% over the past five years .

Back to Top